Clinical trials: Hepatic Disease
Hepatic Disease, Renal Disease
Assess Safety and Performance of the Kronos Electrocautery Device for Electrocautery Procedures Following Coaxial Biopsy Procedures
The primary objective for this study is to assess safety and performance of the Kronos Electrocautery Device for electrocautery procedures following coaxial biopsy procedures on areas that include, but are not limited to, liver…
- Trial name
- NCT05593211
- Testing
- Kronos Electrocautery Device
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Single Pass Inc
Colorectal Cancer with Hepatic Metastases
TATE and KN046 in MCRC
A single-arm, multicenter, Phase IIA study of Intra-arterial Administration of Tirapazamine followed by Transarterial Embolization (TATE) and KN046 (recombinant humanized anti-PD-L1/CTLA-4 bispecific single-domain antibody Fc…
- Trial name
- NCT06834399
- Testing
- KN046 （PD-L1/CTLA4 BsAb）, TATE：Intra-arterial Administration of Tirapazamine followed by Transarterial Embolization
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Zhejiang Raygene Pharmaceuticals Co., Ltd
Diphtheria, Tetanus
Assess Immune Response Following Primary Vaccination With Tritanrix™-HepB Vaccine Mixed With 3 Formulations of Hib-MenAC Vaccine to Infants
To compare three formulations of Hib-MenAC vaccines mixed with Tritanrix™-HepB vaccine with that of Tritanrix™-HepB vaccine concomitantly administered with GSK Biologicals' Hiberix™ vaccine and Tritanrix™-HepB vaccine mixed with…
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT00291967
- Testing
- DTPw-HBV/Hib-MenAC conjugate vaccine
- Where
- Philippines
- Volunteers
- 525 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatocellular Carcinoma
A Study of Anlotinib in Patients With Hepatocellular Carcinoma
To assess the primary effects and safety of Anlotinib with placebo in patients with Hepatocellular Carcinoma(HCC).
- Trial name
- ALTER0802 (NCT02809534)
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis
A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
This study is researching an experimental drug called ALN-CIDEB, also referred to as "study drug". The study is focused on participants with metabolic dysfunction-associated steatotic liver disease (MASLD) (Part A) and metabolic…
- Trial name
- NCT06836609
- Testing
- ALN-CIDEB
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 132 people
- Sponsor
- Regeneron Pharmaceuticals
Poliomyelitis, Diphtheria
Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants
The purpose of this study is to assess the immunogenicity and safety of GSK Biologicals' Infanrix hexa vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar…
- Conditions
- Poliomyelitis, Diphtheria, Haemophilus Influenzae Type b, Tetanus
- Trial name
- NCT02096263
- Testing
- Infanrix hexa, Pediarix, ActHIB
- Where
- 43 sites in United States
- Volunteers
- 585 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Japanese Encephalitis, Hepatitis A
Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children
Safety: To describe the safety profiles following vaccination. Immunogenicity: To describe the immune response after a single dose of vaccine.
- Trial name
- NCT00621764
- Testing
- Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28), Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)
- Where
- 3 sites in Thailand
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Hepatitis C, HCV
A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of ABT-450 with ritonavir (ABT-450/r) dosed in combination with ABT-072 and ribavirin (RBV) in treatment-naïve…
- Conditions
- Hepatitis C, HCV, Chronic Hepatitis C Infection, Hepatitis C Genotype 1
- Trial name
- NCT01221298
- Testing
- ABT-450, ABT-072, Ribavirin
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Wilson's Disease
A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease
The objectives of this clinical trial are to assess, for up to 5 years, the safety, tolerability and pharmacological activity of a single ascending doses of VTX-801, a gene therapy, administered intravenously (IV) to adult…
- Trial name
- GATEWAY (NCT04537377)
- Testing
- VTX-801
- Where
- 10 sites in United States, Denmark and 2 more
- Volunteers
- 4 people
- Sponsor
- Vivet Therapeutics SAS
Hepatitis, Chronic, Hepatitis C Virus
Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus.
Phase 1 study in HVC (Hepatitis C Virus) infected subjects to determine pharmacokinetics, safety and efficacy in subjects with no or inadequate response to prior treatment.
- Trial name
- NCT00671671
- Testing
- Small Molecule Agent (PF-868554)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Pfizer
Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)
This study will evaluate the effect of efinopegdutide administration once every 2 weeks (Q2W) versus once weekly (Q1W) on mean relative reduction from baseline in liver fat content (LFC) after 28 weeks, as well as the safety and…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease, Liver Disease
- Trial name
- NCT06482112
- Testing
- Efinopegdutide
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 124 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Liver Disease
Study to Evaluate the Efficacy and Safety of DWJ1464 in Patients with Chronic Liver Disease
This study aims to assess the effect of DWJ1464 on improvement of liver function in patients with Chronic liver disease. Patients with Chronic liver disease aged 19 years or over will participate in the study.
- Trial name
- NCT06272630
- Testing
- DWJ1464
- Where
- South Korea
- Volunteers
- 263 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Thrombocytopenia Associated With Liver Disease
Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure
This is a global, multicenter, randomized, double-blind, placebo-controlled, parallel group study using avatrombopag to treat adults with thrombocytopenia associated with liver disease.
- Trial name
- NCT01972529
- Testing
- avatrombopag (lower baseline platelet count), avatrombopag (higher baseline platelet count)
- Where
- 109 sites in United States, Argentina and 18 more
- Volunteers
- 231 people
- Sponsor
- Eisai Inc.
Liver Fibrosis, Cirrhosis
FibroTouch Non-invasive Evaluation of Liver Fibrosis and Cirrhosis
This prospective and multicenter study is to determine the diagnostic performance (accuracy, specificity and sensitivity) of transient elastography (FibroTouch) for liver fibrosis assessment in chronic hepatitis B (CHB) patients…
- Conditions
- Liver Fibrosis, Cirrhosis, Chronic Hepatitis B
- Trial name
- NCT02476695
- Testing
- FibroTouch Examination, FibroScan Examination, Ultrasonic B Examination
- Where
- 15 sites in China
- Volunteers
- 412 people
- Sponsor
- Wuxi Hisky Medical Technology Co Ltd
Alpha 1-Antitrypsin Deficiency
Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency
This randomized trial is being conducted to show non-inferiority of OctaAlpha1 compared to Glassia® in terms of the serum trough levels at steady state.
- Trial name
- NCT03385395
- Testing
- OctaAlpha1, Glassia
- Sponsor
- Octapharma
Liver Fibrosis, Hepatic Cirrhosis
Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis
The purpose of this study is to evaluate the safety, tolerability, and pharmacodynamic effects of AZD2389 in adult participants with steatotic liver disease (SLD) and advanced fibrosis.
- Trial name
- BRAVO (NCT07610837)
- Testing
- AZD2389
- Where
- 22 sites in United States, Puerto Rico
- Volunteers
- 104 people
- Sponsor
- AstraZeneca
Hepatitis C, Chronic
Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255)
Although injection drug users represent the majority of new and existing cases of infection with hepatitis C virus (HCV), many lack access to treatment because of concerns about adherence, effectiveness, and reinfection.
- Trial name
- NCT00725751
- Testing
- Pegylated interferon alfa-2b (PegIFN-2b), Ribavirin
- Volunteers
- 353 people
- Sponsor
- Merck Sharp & Dohme LLC
Liver Failure, Acute on Chronic
Safety and Efficacy of Mesenchymal Stem Cell Transplantation for Acute-on-Chronic Liver Failure
Safety and Efficacy of Mesenchymal Stem Cell Transplantation for Acute-on-Chronic Liver Failure
- Trial name
- NCT03863002
- Testing
- Mesenchymal Stem Cell
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Tianjin Weikai Bioeng., Ltd.
Hepatitis C, Chronic
A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED)
SCH 900518 is a potent oral inhibitor of HCV NS3 protease which disrupts hepatitis C virus (HCV) polyprotein processing. SCH 900518, when added to the current standard of care (SOC), peginterferon-alfa plus ribavirin, would…
- Trial name
- NEXT-1 (NCT00797745)
- Testing
- peginterferon alfa 2b, ribavirin, SCH 900518
- Volunteers
- 111 people
- Sponsor
- Merck Sharp & Dohme LLC
Viral Hepatitis
A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection
A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection
- Trial name
- NCT07142811
- Testing
- Tobevibart, Elebsiran, Bulevirtide
- Where
- 31 sites in Belgium, Bulgaria and 9 more
- Volunteers
- 100 people
- Sponsor
- Vir Biotechnology, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.